Rapid Micro Biosystems reported second quarter 2026 financial results with total revenue of $8.1 million, an 11% increase year-over-year. The company achieved a record gross margin of 15%, up from 3.8% in the prior year period, driven by a 2.1% decrease in cost of revenue despite higher sales. Recurring revenue grew 14% to $5.0 million, representing 63% of total revenue. The company reaffirmed its full-year 2026 revenue guidance of $37.0 million to $41.0 million and increased its system validation target to at least 27 placements. Net loss widened slightly to $12.9 million from $11.9 million, with cash and investments totaling approximately $20 million as of June 30, 2026. Rapid Micro Biosystems operates in the life sciences technology industry, providing automation solutions for microbial quality control testing in pharmaceutical manufacturing.